Rituximab-lenalidomide-dexamethasone induces complete and durable remission in relapsed refractory diffuse large B-cell non-Hodgkin lymphoma

Leukemia and Lymphoma

Volumn 51, Issue 9, 2010, Pages 1-3

  Ivanov, Vadim ^a   Tabouret, Emeline ^a   Chuto, Guillaume ^a   Chetaille, Bruno ^a   Fezoui, Hacène ^b   Coso, Diane ^a   Rey, Jerome ^a   Aurran Schleinitz, Therese ^a   Schiano, Jean Marc ^a   Stoppa, Anne Marie ^a   Blaise, Didier ^a   Bouabdallah, Reda ^a  

^a INSTITUT PAOLI CALMETTES   (France)

^b Hopital Font Pré   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CARMUSTINE; CD20 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; LENALIDOMIDE; MELPHALAN; METHOTREXATE; PREDNISONE; PROTEIN BCL 2; RITUXIMAB; VINCRISTINE; VINDESINE;

ABDOMINAL PAIN; AGED; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PALLIATIVE THERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CANCER SURGERY; CASE REPORT; COLON TUMOR; COLONOSCOPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIARRHEA; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LETTER; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 77956321373     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.497886     Document Type: Letter

References (12)

1. Witzig TE, Vose JM, Kaplan HP, et al. Early results from a phase II study of lenalidomide monotherapy in relapsed/ refractory indolent non-Hodgkin's lymphoma. Blood 2006;108(Suppl. 1): (Abstract 2482).
2. Wiernik PH, Lossos I, Tuscano J, et al. Preliminary results from a phase II study of lenalidomide monotherapy in relapsed/refractory aggressive non-Hodgkin's lymphoma. Blood 2006;108(Suppl. 1): (Abstract 531).
3. Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008;26:4952-4957.
4. Witzig TE, Vose JM, Zinzani PL, et al. Durable responses after lenalidomide oral monotherapy in patients with relapsed or refractory (R/R) aggressive non-Hodgkin's lymphoma (a- NHL): results from an international phase 2 study (CC-5013- NHL-003). Blood 2009;114(Suppl. 1): (Abstract 1676).
5. Habermann TM, Lossos IS, Justice G, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009;145:344-349.
6. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-282.
7. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004;4:314-322.
8. Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, Ottman E, Czuczman MS. Immunomodulatory drug CC-5013 or CC- 4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res 2005;11:5984-5992.
9. Wu L, Adams M, Carter T, et al. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+tumor cells. Clin Cancer Res 2008;14:4650-4657.
10. Zhang L, Qian Z, Cai Z, et al. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol 2009;84:553-559.
11. Kaufmann H, Raderer M, Wohrer S, et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed/ refractory mantle cell lymphoma. Blood 2004;104:2269-2271.
12. Wang L, Fayad L, Hagemeister FB, et al. A phase I/II study of lenalidomide in combination with rituximab in relapsed/ refractory mantle cell lymphoma. Blood 2009;114(Suppl. 1): (Abstract 2719).